Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas

References

• Staal S P, Hartley J W. Thymic lymphoma induction by the AKT8 murine retrovirus. Journal of Experimental Medicine 1988; 167: 1259–1264
   PubMed Web of Science ®Google Scholar
• Ahmed N N, Franke T F, Bellacosa A, Datta K, Gonzalez-Portal M E, Taguchi T. The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential. Oncogene 1993; 8: 1957–1963
   PubMed Web of Science ®Google Scholar
• Bellacosa A, Testa J R, Staal S P, Tsichlis P N. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991; 254: 274–277
   PubMed Web of Science ®Google Scholar
• Brazil D P, Hemmings B A. Ten years of protein kinase B signalling: a hard Akt to follow. Trends in Biochemical Science 2001; 26: 657–664
   PubMed Web of Science ®Google Scholar
• Coffer P J, Woodgett J R. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. European Journal of Biochemistry 1991; 201: 475–481
   PubMedGoogle Scholar
• Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Current Opinions in Cellular Biology 1998; 10: 262–267
   PubMed Web of Science ®Google Scholar
• Alessi D R, Cohen P. Mechanism of activation and function of protein kinase B. Current Opinions in Genetic Development 1998; 8: 55–62
   PubMed Web of Science ®Google Scholar
• Andjelkovic M, Alessi D R, Meier R, Fernandez A, Lamb N J, Frech M. Role of translocation in the activation and function of protein kinase B. Journal of Biological Chemistry 1997; 272: 31515–31524
   PubMed Web of Science ®Google Scholar
• Eves E M, Xiong W, Bellacosa A, Kennedy S G, Tsichlis P N, Rosner M R, Hay N. Akt, a target of phosphatidylinositol3-kinase, inhibits apoptosis in a differentiating neuronal cell line. Molecular Cell Biology 1998; 18: 2143–2152
   PubMed Web of Science ®Google Scholar
• Al-Sakkaf K A, Mooney L M, Dobson P R, Brown B L. Possible role for protein kinase B in the anti-apoptotic effect of prolactin in rat Nb2 lymphoma cells. Journal of Endocrinology 2000; 167: 85–92
   PubMed Web of Science ®Google Scholar
• Blanc A, Pandey N R, Srivastava A K. Synchronous activation of ERK 1/2, p38mapk and PKB/Akt signaling by H2O2 in vascular smooth muscle cells: Potential involvement in vascular disease (Review). International Journal of Molecular Medicine 2003; 11: 229–234
   PubMed Web of Science ®Google Scholar
• Cross D A, Alessi D R, Cohen P, Andjelkovich M, Hemmings B A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785–789
   PubMed Web of Science ®Google Scholar
• Kane L P, Shapiro V S, Stokoe D, Weiss A. Induction of NF-kappaB by the Akt/PKB kinase. Current Biology 1999; 9: 601–604
   PubMed Web of Science ®Google Scholar
• Bai R Y, Ouyang T, Miething C, Morris S W, Peschel C, Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000; 96: 4319–4327
   PubMed Web of Science ®Google Scholar
• Lauder A, Castellanos A, Weston K. c-Myb transcription is activated by protein kinase B (PKB) following interleukin 2 stimulation of T cells and is required for PKB-mediated protection from apoptosis. Molecular Cell Biology 2001; 21: 5797–5805
   PubMed Web of Science ®Google Scholar
• Hideshima T, Nakamura N, Chauhan D, Anderson K C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001; 20: 5991–6000
   PubMed Web of Science ®Google Scholar
• Yoo J K, Cho J H, Lee S W, Sung Y C. IL-12 provides proliferation and survival signals to murine CD4 + T cells through phosphatidylinositol 3-kinase/Akt signaling pathway. Journal of Immunology 2002; 169: 3637–3643
   PubMed Web of Science ®Google Scholar
• Brennan P, Babbage J W, Burgering B M, Groner B, Reif K, Cantrell D A. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity 1997; 7: 679–689
   PubMed Web of Science ®Google Scholar
• Kops G J, Medema R H, Glassford J, Essers M A, Dijkers P F, Coffer P J, Lam E W, Burgering B M. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Molecular Cell Biology 2002; 22: 2025–2036
   PubMed Web of Science ®Google Scholar
• Testa J R, Bellacosa A. Membrane translocation and activation of the Akt kinase in growth factor-stimulated hematopoietic cells. Leukemia Research 1997; 21: 1027–1031
   PubMed Web of Science ®Google Scholar
• Cheng J Q, Godwin A K, Bellacosa A, Taguchi T, Franke T F, Hamilton T C. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proceedings of the National Academy of Sciences (USA) 1992; 89: 9267–9271
   PubMed Web of Science ®Google Scholar
• Nakatani K, Sakaue H, Thompson D A, Weigel R J, Roth R A. Identification of a human Akt3 (protein kinase B gamma) which contains the regulatory serine phosphorylation site. Biochemistry & Biophysics Research Communications 1999; 257: 906–910
   PubMed Web of Science ®Google Scholar
• Zinda M J, Johnson M A, Paul J D, Horn C, Konicek B W, Lu Z H. AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. Clinical Cancer Research 2001; 7: 2475–2479
   PubMed Web of Science ®Google Scholar
• Okano J, Gaslightwala I, Birnbaum M J, Rustgi A K, Nakagawa H. Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. Journal of Biological Chemistry 2000; 275: 30934–30942
   PubMed Web of Science ®Google Scholar
• Pekarsky Y, Hallas C, Croce C M. The role of TCL1 in human T-cell leukemia. Oncogene 2001; 20: 5638–5643
   PubMed Web of Science ®Google Scholar
• Nicholson K M, Anderson N G. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14: 381–395
   PubMed Web of Science ®Google Scholar
• Aoki M, Batista O, Bellacosa A, Tsichlis P, Vogt P K. The akt kinase: molecular determinants of oncogenicity. Proceedings of the National Academy of Sciences (USA) 1998; 95: 14950–14955
   PubMed Web of Science ®Google Scholar
• Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed J C. The AKT kinase is activated in multiple myeloma tumor cells. Blood 2001; 98: 2853–2855
   PubMed Web of Science ®Google Scholar
• Bacus S S, Altomare D A, Lyass L, Chin D M, Farrell M P, Gurova K. AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 2002; 21: 3532–3540
   PubMed Web of Science ®Google Scholar
• Testa J R, Bellacosa A. AKT plays a central role in tumorigenesis. Proceedings of the National Academy of Sciences (USA) 2001; 98: 10983–10985
   PubMed Web of Science ®Google Scholar
• Luo J, Manning B D, Cantley L C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003; 4: 257–262
   PubMed Web of Science ®Google Scholar
• Gu T L, Tothova Z, Scheijen B, Griffin J D, Gilliland D G, Sternberg D W. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood 2004; 103: 4622–4629
   PubMed Web of Science ®Google Scholar
• Rassidakis G Z, Feretzaki M, Atwell C, Grammatikakis I, Lin Q, Lai R. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood 2005; 105: 827–829
   PubMed Web of Science ®Google Scholar
• Slupianek A, Skorski T. NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner. Experimental Hematology 2004; 32: 1265–1271
   PubMed Web of Science ®Google Scholar
• Cantrell D. Protein kinase B (Akt) regulation and function in T lymphocytes. Seminars in Immunology 2002; 14: 19–26
   PubMed Web of Science ®Google Scholar
• Walsh P T, Smith L M, O'Connor R. Insulin-like growth factor-1 activates Akt and Jun N-terminal kinases (JNKs) in promoting the survival of T lymphocytes. Immunology 2002; 107: 461–471
   PubMed Web of Science ®Google Scholar
• Reif K, Burgering B M, Cantrell D A. Phosphatidylinositol 3-kinase links the interleukin-2 receptor to protein kinase B and p70 S6 kinase. Journal of Biological Chemistry 1997; 272: 14426–14433
   PubMed Web of Science ®Google Scholar
• Kelly E, Won A, Refaeli Y, Van Parijs L. IL-2 and related cytokines can promote T cell survival by activating AKT. Journal of Immunology 2002; 168: 597–603
   PubMed Web of Science ®Google Scholar
• Diebold J. Classification of malignant lymphoma. WHO international proposal. Annals of Pathology 1998; 18: 361–367
   PubMed Web of Science ®Google Scholar
• Clark A S, West K, Streicher S, Dennis P A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Molecular Cancer Therapy 2002; 1: 707–717
   PubMed Web of Science ®Google Scholar
• Page C, Lin H J, Jin Y, Castle V P, Nunez G, Huang M, Lin J. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Research 2000; 20: 407–416
   PubMed Web of Science ®Google Scholar
• Datta S R, Brunet A, Greenberg M E. Cellular survival: a play in three Akts. Genes Development 1999; 13: 2905–2927
   PubMed Web of Science ®Google Scholar
• Alkan S, Izban K F. Immunohistochemical localization of phosphorylated AKT in multiple myeloma. Blood 2002; 99: 2278–2279
   PubMed Web of Science ®Google Scholar
• Gygi S P, Rochon Y, Franza B R, Aebersold R. Correlation between protein and mRNA abundance in yeast. Molecular Cell Biology 1999; 19: 1720–1730
   PubMed Web of Science ®Google Scholar
• Yuan Z Q, Sun M, Feldman R I, Wang G, Ma X, Jiang C. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000; 19: 2324–2330
   PubMed Web of Science ®Google Scholar
• Malik S N, Brattain M, Ghosh P M, Troyer D A, Prihoda T, Bedolla R, Kreisberg J I. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clinical Cancer Research 2002; 8: 1168–1171
   PubMed Web of Science ®Google Scholar
• Sun M, Wang G, Paciga J E, Feldman R I, Yuan Z Q, Ma X L. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. American Journal of Pathology 2001; 159: 431–437
   PubMed Web of Science ®Google Scholar
• Rathmell J C, Elstrom R L, Cinalli R M, Thompson C B. Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma. European Journal of Immunology 2003; 33: 2223–2232
   PubMed Web of Science ®Google Scholar
• Dahia P L, Aguiar R C, Alberta J, Kum J B, Caron S, Sill H. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Human Molecular Genetics 1999; 8: 185–193
   PubMed Web of Science ®Google Scholar
• Choi Y, Zhang J, Murga C, Yu H, Koller E, Monia B P. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene 2002; 21: 5289–5300
   PubMed Web of Science ®Google Scholar
• Hyun T, Yam A, Pece S, Xie X, Zhang J, Miki T. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood 2000; 96: 3560–3568
   PubMed Web of Science ®Google Scholar
• Xu Z, Stokoe D, Kane L P, Weiss A. The inducible expression of the tumor suppressor gene PTEN promotes apoptosis and decreases cell size by inhibiting the PI3K/Akt pathway in Jurkat T cells. Cell Growth Difference 2002; 13: 285–296
   PubMedGoogle Scholar
• Stiles B, Gilman V, Khanzenzon N, Lesche R, Li A, Qiao R, Liu X, Wu H. Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis. Molecular Cell Biology 2002; 22: 3842–3851
   PubMed Web of Science ®Google Scholar
• Pekarsky Y, Hallas C, Croce C M. Molecular basis of mature T-cell leukemia. JAMA 2001; 286: 2308–2314
   PubMed Web of Science ®Google Scholar
• Takaishi H, Konishi H, Matsuzaki H, Ono Y, Shirai Y, Saito N. Regulation of nuclear translocation of forkhead transcription factor AFX by protein kinase B. Proceedings of the National Academy of Sciences (USA) 1999; 96: 11836–11841
   PubMed Web of Science ®Google Scholar
• Burgering B M, Medema R H. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. Journal of Leukocyte Biology 2003; 73: 689–701
   PubMed Web of Science ®Google Scholar
• Pekarsky Y, Koval A, Hallas C, Bichi R, Tresini M, Malstrom S. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proceedings of the National Academy of Sciences (USA) 2000; 97: 3028–3033
   PubMed Web of Science ®Google Scholar
• Borgatti P, Martelli A M, Bellacosa A, Casto R, Massari L, Capitani S, Neri L M. Translocation of Akt/PKB to the nucleus of osteoblast-like MC3T3-E1 cells exposed to proliferative growth factors. FEBS Letters 2000; 477: 27–32
   PubMed Web of Science ®Google Scholar
• Laine J, Kunstle G, Obata T, Noguchi M. Differential regulation of Akt kinase isoforms by the members of the TCL1 oncogene family. Journal of Biological Chemistry 2002; 277: 3743–3751
   PubMed Web of Science ®Google Scholar
• Teitell M, Damore M A, Sulur G G, Turner D E, Stern M H, Said J W. TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues. Proceedings of the National Academy of Sciences (USA) 1999; 96: 9809–9814
   PubMed Web of Science ®Google Scholar
• Narducci M G, Pescarmona E, Lazzeri C, Signoretti S, Lavinia A M, Remotti D. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Research 2000; 60: 2095–2100
   PubMed Web of Science ®Google Scholar